MIGS
New findings ‘alter forever how we think of MIGS’ – Dr Ike Ahmed
Ivantis has revealed new data from its five-year HORIZON pivotal trial showing its Hydrus Microstent device lowers the rate of ...
Alcon to acquire Hydrus Microstent MIGS device for AU$640 million
Multinational ophthalmic company Alcon has agreed to acquire privately-owned Californian firm Ivantis – and its Hydrus Microstent minimally invasive glaucoma ...
It’s all about the (aqueous) flow
When it comes to the treatment of glaucoma, there is growing evidence to suggest that the ability to re-establish the ...
New data shows iTrack efficacy as both standalone and combined MIGS procedure
Nova Eye Medical has published two-year data for its iTrack ab-interno canaloplasty procedure, which it says showed an average reduction ...
Making a stand for MBGS under Medicare
Advances in glaucoma stent technology far outstripped the Medicare schedule early on, creating a disconnect that had far-reaching consequences. As ...
Public MIGS funding a step closer for iTrack in Australia
Nova Eye Medical has announced an application to secure public funding for its iTrack ab-interno canaloplasty as a standalone minimally ...
2020: a year like no other
Insight takes a look at the innovations, breakthroughs, setbacks, events and stories that shaped the Australian ophthalmic sector in 2020. ...
Aussie firm pushes for Medicare wording change to standalone MIGS
Nova Eye Medical is seeking a modification to the existing minimally invasive glaucoma surgery (MIGS) Medicare item number that only ...
Aussie firm reveals next-gen MIGS device in pipeline
Adelaide ophthalmic device manufacturer Nova Eye Medical is developing a next generation iTrack glaucoma surgical system to reduce operating times. ...